Medicenna Announces Results of Annual Meeting of Shareholders
TORONTO and HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the voting results from the Company’s annual meeting of shareholders held today, September 21, 2022 (the "Meeting").
Medicenna is pleased to announce that all of the nominees listed in the management proxy circular dated August 2, 2022 were elected as directors. Each of the directors was elected with greater than 97% of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote are detailed below:
Medicenna shareholders also voted to appoint PricewaterhouseCoopers LLP as auditor of the Company.
A total of 57.468% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.
For further information about the Company please contact:
Elizabeth Williams, Chief Financial Officer, 416-648-5555, [email protected]
For more investor information, please contact:
Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, [email protected]